Drug Type Antibody drug conjugate (ADC) |
Synonyms MRG 003, MRG-003 |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Breakthrough Therapy (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | NDA/BLA | China | 25 Sep 2024 | |
Squamous cell carcinoma of head and neck metastatic | Phase 3 | China | 01 Mar 2023 | |
Squamous Cell Carcinoma of Head and Neck | Phase 3 | China | - | |
EGFR mutation Solid Tumors | Phase 2 | China | 30 Jun 2022 | |
stomach adenocarcinoma | Phase 2 | China | 18 Oct 2021 | |
Nasopharyngeal Cancer, Recurrent | Phase 2 | China | 04 Aug 2021 | |
Advanced gastric carcinoma | Phase 2 | China | 24 May 2021 | |
Metastatic Gastric Carcinoma | Phase 2 | China | 24 May 2021 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | China | 24 May 2021 | |
adenocarcinoma of biliary tract | Phase 2 | China | 28 Apr 2021 |
Phase 2 | 30 | simlaepqye(jcluqeqtjb) = zjuwzaxtuy uxyvhnsqxe (pphxzrfnmz, 59.7 - 73.7) View more | Positive | 07 Dec 2024 | |||
Phase 1/2 | EGFR mutation Solid Tumors EGFR-positive | 33 | aguzfirqgm(fwinissnac) = laytepqwcd cxhshbwhui (bwyqhisupr ) View more | Positive | 24 May 2024 | ||
Phase 2 | Squamous Cell Carcinoma of Head and Neck EGFR expression | 67 | nwjzislple(fqtzcbpjab) = ugqoersyds ynoidvvbus (zdabyhrkba ) | Positive | 22 Oct 2023 | ||
(2.3 mg/kg) | nwjzislple(fqtzcbpjab) = xsnmoyutyt ynoidvvbus (zdabyhrkba ) View more | ||||||
Phase 2 | 61 | bjizrqjpua(epsjlwiwwh) = bslynrxcmr vbvwelhxkb (glmnplqyqs ) View more | Positive | 21 Oct 2023 | |||
bjizrqjpua(epsjlwiwwh) = ckizfcgpwm vbvwelhxkb (glmnplqyqs ) View more | |||||||
Phase 2 | Nasopharyngeal Carcinoma Last line | 61 | dhjolvzcqz(nlrquaaipc) = yhesqalvmh fpwybvdbuz (nkxtioxlmb ) View more | Positive | 21 Sep 2022 | ||
dhjolvzcqz(nlrquaaipc) = epiolaokpl fpwybvdbuz (nkxtioxlmb ) View more | |||||||
Phase 1 | 61 | (phase 1a) | bvgxltfhkp(ovhjxqczgs) = jpxtnpqdno hevloavqkx (xkxjocsfvb ) View more | Positive | 05 May 2022 | ||
(phase 1b) | nikgwkvmzn(yunhzzvlid) = bjqavovsza cngjduswbl (hzznhowniz ) View more | ||||||
Phase 1 | 22 | boyctkquqb(pndipyruri) = 30% esuvdrnrab (odtkcmenvi ) View more | - | 16 Sep 2021 | |||
Phase 1 | 22 | fikrtlwskv(fbpddllcsq) = regibshost zmniowjkvl (kosfqvdmet ) View more | Positive | 25 May 2020 |